[Featured Stock] Kumho HT, Dinona Demonstrates Efficacy in Monkey Trials of COVID-19 Treatment... 'Strong Performance'

[Asia Economy Reporter Yoo Hyun-seok] Kumho HT is showing strong performance. It appears that the news of 'Dainona,' which is pursuing a merger, proving the therapeutic efficacy of its COVID-19 treatment candidate 'DNP002' in monkey trials has had an impact.

As of 2:20 PM on the 31st, Kumho HT was trading at 4,355 KRW, up 24.43% (855 KRW) compared to the previous trading day.

On the same day, Dainona announced that its self-developed antibody drug 'DNP002' demonstrated efficacy against neutrophilia caused by the novel coronavirus infection (COVID-19) in non-clinical trials on monkeys.

Recent academic research results indicate that most deaths caused by COVID-19 infection are due to acute respiratory distress syndrome. Analysis of COVID-19 patients points to excessive neutrophilia, where neutrophils excessively infiltrate the lungs, as a cause of death.

Dainona's DNP002 was proven through primate trials to reduce neutrophil levels by about half, which are the neutrophils that lead to death, according to monkey experiment results.

Dainona plans to conduct a Phase 1 clinical trial targeting solid tumors, recently approved by the Ministry of Food and Drug Safety, alongside the development of the COVID-19 treatment using DNP002.

This content was produced with the assistance of AI translation services.